Department of Neurological Surgery, Loyola University Medical Center, Maywood, Illinois, USA.
Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.
World Neurosurg. 2024 Feb;182:e98-e106. doi: 10.1016/j.wneu.2023.11.053. Epub 2023 Nov 22.
Neurosurgeons treat nonfunctioning pituitary adenomas by surgical resection. Based on the adherence of the tumor to the normal pituitary gland, operative risks may include hormone replacement therapy for postoperative hypopituitarism with gross total resection that injures the gland or recurrent tumor with subtotal resection and purposeful avoidance of gland manipulation. None of the patients presented in this article had a preoperative preference regarding extent of resection. This study aimed to evaluate postoperative patient preferences regarding extent of resection.
Adult patients who underwent resection of adenomas between 2015 and 2023 were retrospectively reviewed and surveyed. After surgery, participating patients were asked for their preference regarding 100% tumor resection with lifelong daily hormone replacement therapy versus 90% tumor resection with a chance of recurrence in the hypothetical situation where the neurosurgeon encounters tumor adherent to the normal gland.
Of the 73 patients included, 54 (74.0%) responded to the survey, with the majority (36 [66.7%]) preferring 90% resection with the chance of tumor recurrence. Tumor recurrence (odds ratio 2.3, 95% confidence interval 2.1-2.5, P = 0.03) and steroid avoidance (odds ratio 2.2, 95% confidence interval 2.0-2.4, P = 0.04) were the 2 variables that were significant predictors of patient preference in multivariate regression analysis.
Although patients may not have the preoperative insight or experience to have a strong conviction regarding the extent of adenoma resection, the consequences following surgery clearly influence their preference. Most patients in our study, including patients with gross total resection and especially patients who experienced side effects of steroid therapy, preferred subtotal resection with the chance of tumor recurrence over hormone replacement therapy.
神经外科医生通过手术切除来治疗无功能垂体腺瘤。根据肿瘤与正常垂体的附着程度,手术风险可能包括因全切除肿瘤而导致术后垂体功能减退,需要激素替代治疗,或因次全切除肿瘤并故意避免腺体操作而导致肿瘤复发。本文介绍的患者在术前均未对切除范围有偏好。本研究旨在评估术后患者对切除范围的偏好。
回顾性分析 2015 年至 2023 年间接受腺瘤切除术的成年患者,并对其进行调查。手术后,让参与调查的患者在以下两种情况下选择自己的偏好:100%肿瘤切除,需要终身每日接受激素替代治疗;90%肿瘤切除,有肿瘤在紧贴正常腺体的情况下复发的可能。
在纳入的 73 例患者中,有 54 例(74.0%)对调查做出了回应,其中大多数(36 例[66.7%])更倾向于 90%肿瘤切除,并有肿瘤复发的可能。肿瘤复发(比值比 2.3,95%置信区间 2.1-2.5,P=0.03)和避免使用类固醇(比值比 2.2,95%置信区间 2.0-2.4,P=0.04)是多变量回归分析中对患者偏好有显著预测作用的 2 个变量。
尽管患者可能在术前没有洞察力或经验来对腺瘤切除术的范围有强烈的信念,但手术后的结果显然会影响他们的偏好。我们的研究中,大多数患者(包括行全切除手术的患者,尤其是经历类固醇治疗副作用的患者)更倾向于选择有肿瘤复发可能的次全切除术,而不是激素替代治疗。